Impax Labs (IPXL) Tops Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St hits two-week lows as rising bond yields, Walmart results drag
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Piper Jaffray Downgrades Impax Laboratories (IPXL) to Neutral
November 5, 2014 6:39 AM ESTPiper Jaffray downgraded Impax Laboratories (NASDAQ: IPXL) from Overweight to Neutral with a price target of $31.00 (from $35.00) following Q3 results and several question marks.
Analyst David Amsellem comments, "IPXL reported diluted EPS of $0.33, just north of the Street estimate. With IPXL using up its... More
